Dr. Alberto Chiappori, MD – Tampa, FL

Overview of Dr. Chiappori

Dr. Alberto Chiappori is an oncologist in Tampa, FL and is affiliated with H. Lee Moffitt Cancer Center and Research Institute. He received his medical degree from Cayetano Heredia University and has been in practice 28 years. Dr. Chiappori accepts several types of health insurance, listed below. He is one of 171 doctors at H. Lee Moffitt Cancer Center and Research Institute who specialize in Oncology. He has more than 100 publications and over 500 citings.

Education & Training

• Vanderbilt University Medical CenterFellowship, Hematology and Medical Oncology, 1993 - 1997

• Southern Illinois UniversityResidency, Internal Medicine, 1990 - 1993

• Cayetano Heredia UniversityClass of 1989

Certifications & Licensure

• FL State Medical License 2001 - 2025

• KY State Medical License 1997 - 2002

• IL State Medical License 1990 - 1999

Clinical Trials

Publications & Presentations

PubMed

• Phase 2 Trial of Nivolumab and Ramucirumab for Relapsed Mesothelioma: HCRN-LUN15-299.

  Xi, M., Dudek, A., Scilla, K., Mamdani, H., Creelan, B., Saltos, A., Tanvetyanon, T., Chiappori, A.> ;JTO Clinical and Research Reports. 2023 Dec 1

• Osimertinibafatinib as first-line treatment for patients with metastatic non-small cell lung cancer with anexon 19 deletion or exon 21 L858R mutation.

  Gilardone, S., Thapa, R., Laborde, J., Chen, D., Melzer, D., Pellini, B., Shafique, M., Saltos, A., Creelan, B., Tanvetyanon, T., Chiappori, A., Simon, G., Haura, E., ...> ;Journal of Thoracic Disease. 2023 Nov 30

• A phase I/IB trial of binimetinib in combination with erlotinib in NSCLC harboring activating KRAS or EGFR mutations.

  Andreas N Saltos, Ben C Creelan, Tawee Tanvetyanon, Alberto A Chiappori, Scott J Antonia, Michael R Shafique, Milijana Ugrenovic-Petrovic, Samer Sansil, Anthony Neuger...> ;Lung Cancer. 2023 Sep 1
• Join now to see all

Journal Articles

• Overall Survival with Durvalumab After Chemoradiotherapy in Stage III NSCLC  

  David R Spigel, Davey Daniel, Jhanelle E Gray, Augusto Villegas, Tarek Mekhail, Alberto Chiappori, The New England Journal of Medicine

Lectures

• Phase I/II study of the A2AR antagonist NIR178 (PBF-509), an oral immunotherapy, in patients (pts) with advanced NSCLC. 

  2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018

Press Mentions

• Mesothelioma Find Out About Explores New Remedy When Chemotherapy FailsAugust 27th, 2021

• Mesothelioma Study Explores New Treatment When Chemotherapy FailsAugust 26th, 2019

Professional Memberships

Hospital Affiliations

Insurance Accepted

• Aetna Choice POS II
  Aetna HMO
  AvMed Health Open Access
  BCBS Blue Card PPO
  BCBS Florida BlueCare HMO
  BCBS Florida NetworkBlue
  BCBS Florida Preferred Patient Care PPO
  CIGNA HMO
  CIGNA Open Access
  

  CIGNA PPO
  Coventry Florida - Employer Group PPO
  First Health PPO
  Great West PPO
  Humana ChoiceCare Network PPO
  Multiplan PHCS PPO
  Multiplan PPO
  United Healthcare - Direct Choice Plus POS
  United Healthcare - Direct Options PPO
  

• Please verify your coverage with the provider's office directly when scheduling an appointment